The most recent ASPREE report (1) can be set in broader context. A systematic review and meta-analysis of primary prevention trials, which included ASPREE, found aspirin gave a non-significant reduction of all-cause mortality by 3% (relative risk 0.97, 95% confidence interval 0.93-1.01). The problem with all trials, however, is treatment Read more
Harnessing aspirin’s potential to improve prevention, treatment, and healthy ageing across the cancer journey. This aligns with the latest research on cancer: recommendations for prevention and innovation that could greatly influence future therapies. Based on the findings of intensive research and particularly informed by the relative safety of aspirin, we Read more
by The Welsh Aspirin Group Peter Elwood, Gareth Morgan, Richard Adams, Christine Delon, Marcus Longley, Simon Noble, Janet Pickering, Majd Protty, John Watkins, Anna Yeatman Corresponding author: Gareth Morgan ABSTRACT: Aspirin is a remarkable drug that has been shown in more than fifty years of research to be beneficial at Read more
Myeloproliferative neoplasms (MPN’s) are a group of blood cancers. MPN’s are bone marrow disorders which results in an excess of blood cells. As a result, these blood cancers are associated with risks of clots and low-dose aspirin is often used in many patients along with other treatments. There are three Read more
Addendum: Since publishing this article, two trials have been subsequently published on aspirin and bowel cancer. They have mixed results and neither study found a statistically significant effect. The table and the commentary will be updated in due course to take account of these studies. (WAG 13/7/2026) https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA3511 https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA3508 Abstract Read more